Eli Lilly and Company (LLY.SW)
Swiss - Swiss Delayed price. Currency in CHF
Add to watchlist
At close: 04:38PM CEST
| Previous close | 690.00 |
| Open | 690.00 |
| Bid | 660.00 x 0 |
| Ask | 785.00 x 0 |
| Day's range | 690.00 - 690.00 |
| 52-week range | 348.00 - 740.00 |
| Volume | |
| Avg. volume | 2,279 |
| Market cap | 656.029B |
| Beta (5Y monthly) | 0.37 |
| PE ratio (TTM) | 129.94 |
| EPS (TTM) | 5.31 |
| Earnings date | 30 Apr 2024 |
| Forward dividend & yield | 4.56 (0.66%) |
| Ex-dividend date | 14 Feb 2024 |
| 1y target est | N/A |
Zacks4 Large Drug Stocks to Hold on to Amid Industry Challenges
Drug and biotech companies are likely to see significant innovation. In the Large-Cap Pharmaceuticals industry, Eli Lilly (LLY), Novo Nordisk (NVO), Merck (MRK) and AbbVie (ABBV) are worth retaining in one's portfolio.
ZacksAnalysts Estimate Pfizer (PFE) to Report a Decline in Earnings: What to Look Out for
Pfizer (PFE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ZacksShould Eli Lilly (LLY) Be in Your Portfolio Ahead of Q1 Earnings?
Eli Lilly (LLY) enjoys strong fundamentals and is expected to consistently do well, mainly supported by its new drugs and its solid pipeline.
© 2024 Yahoo. All rights reserved.